186 related articles for article (PubMed ID: 34076745)
21. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
22. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
23. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.
Minamimoto R; Karam A; Jamali M; Barkhodari A; Gambhir SS; Dorigo O; Iagaru A
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1047-55. PubMed ID: 26611425
[TBL] [Abstract][Full Text] [Related]
24.
Mittlmeier LM; Unterrainer M; Rodler S; Todica A; Albert NL; Burgard C; Cyran CC; Kunz WG; Ricke J; Bartenstein P; Stief CG; Ilhan H; Staehler M
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2031-2037. PubMed ID: 33369689
[TBL] [Abstract][Full Text] [Related]
25. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.
Wang S; Zhu H; Ding J; Wang F; Meng X; Ding L; Zhang Y; Li N; Yao S; Sheng X; Yang Z
Clin Nucl Med; 2021 May; 46(5):382-388. PubMed ID: 33512952
[TBL] [Abstract][Full Text] [Related]
26. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
27. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
van der Hiel B; Haanen JBAG; Stokkel MPM; Peeper DS; Jimenez CR; Beijnen JH; van de Wiel BA; Boellaard R; van den Eertwegh AJM;
BMC Cancer; 2017 Sep; 17(1):649. PubMed ID: 28915798
[TBL] [Abstract][Full Text] [Related]
29. Interim [
Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
[TBL] [Abstract][Full Text] [Related]
30. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors.
Menon BK; Kalshetty A; Bhattacharjee A; Basu S
Nucl Med Commun; 2020 Oct; 41(10):1095-1099. PubMed ID: 32732598
[TBL] [Abstract][Full Text] [Related]
31. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
[TBL] [Abstract][Full Text] [Related]
32. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
[TBL] [Abstract][Full Text] [Related]
33. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.
Signore A; Annovazzi A; Barone R; Bonanno E; D'Alessandria C; Chianelli M; Mather SJ; Bottoni U; Panetta C; Innocenzi D; Scopinaro F; Calvieri S
J Nucl Med; 2004 Oct; 45(10):1647-52. PubMed ID: 15471828
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto R; Zaba LC; Rosenberg J; Reddy SA; Nobashi TW; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2787-2795. PubMed ID: 32296882
[TBL] [Abstract][Full Text] [Related]
35.
Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive monitoring of cancer therapy induced activated T cells using [
Hartimath SV; Draghiciu O; van de Wall S; Manuelli V; Dierckx RA; Nijman HW; Daemen T; de Vries EF
Oncoimmunology; 2017; 6(1):e1248014. PubMed ID: 28197364
[TBL] [Abstract][Full Text] [Related]
37. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
38. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.
Telang S; Rasku MA; Clem AL; Carter K; Klarer AC; Badger WR; Milam RA; Rai SN; Pan J; Gragg H; Clem BF; McMasters KM; Miller DM; Chesney J
BMC Cancer; 2011 Dec; 11():515. PubMed ID: 22165955
[TBL] [Abstract][Full Text] [Related]
40. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
